Genmab CEO eyes big opportunities in global biotech downswing

New guidelines from the US Food and Drug Administration and the continued downswing within the biotech industry at large provide a range of new opportunities for Danish biotech firm Genmab, says CEO Jan van de Winkel.
Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab
Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

The global biotech industry’s battering on the stock market in recent months doesn’t have to be all bad news, says Jan van de Winkel, the CEO of Danish biotech firm Genmab, which has also been impacted on the stock exchange.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading